{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:48:08Z","timestamp":1791830888564,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antiplatelet therapy-associated intracerebral hemorrhage (APT-ICH) remains a significant neurological concern due to high morbidity and mortality among these patients. Early trials of desmopressin (DDAVP) suggested clinical benefit; however, the number of studies available at the time was limited. This systematic review and Bayesian meta-analysis aim to answer whether administration of DDAVP among patients with APT-ICH improves clinical course. Five databases were searched for studies comparing DDAVP and placebo\/control\/usual care in patients with APT-ICH. Bayesian meta-analysis was performed using a random-effects model with three different priors. A total of seven studies were included. There was no difference in overall mortality [odds ratio (OR) 1.23; 95% credible interval (CrI) 0.79\u20131.91], in-hospital mortality (OR 1.41; 95% CrI 0.88\u20132.26), or good functional outcome (OR 0.66; 95% CrI 0.34\u20131.31). Posterior distribution analysis suggested a possible increase in thromboembolic complications and the proportion of patients with poor neurological outcomes among patients on DDAVP. There is currently a lack of convincing evidence of benefit regarding the administration of DDAVP for patients with APT-ICH. Furthermore, there are several signals that raise concerns for harm.<\/jats:p>\n                  <jats:p>This review indicates that there is no clear, well-supported recommendation to administer DDAVP to patients with APT-ICH.<\/jats:p>\n                  <jats:p>The results of Bayesian meta-analysis reveal a concerning signal for harm with DDAVP administration.<\/jats:p>","DOI":"10.1007\/s12028-026-02672-3","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:27:41Z","timestamp":1791829661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0281-5417","authenticated-orcid":false,"given":"Pawe\u0142","family":"\u0141ajczak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Reis","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"\u0141ajczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wellingson Silva","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Bertani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"5","key":"2672_CR1","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/STROKEAHA.120.032550","volume":"52","author":"SM Fernando","year":"2021","unstructured":"Fernando SM, Qureshi D, Talarico R, Tanuseputro P, Dowlatshahi D, Sood MM, et al. Intracerebral hemorrhage incidence, mortality, and association with oral anticoagulation use. Stroke. 2021;52(5):1673\u201381.","journal-title":"Stroke"},{"key":"2672_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaf091","author":"J Grundtvig","year":"2025","unstructured":"Grundtvig J, Gaist D, Christensen L, Ovesen C, Havsteen I, Iversen HK, et al. Risk-factors and multimorbidity in oral anticoagulant-related intracerebral haemorrhage: a comparison of patients in pivotal trials and real life. Age Ageing. 2025. https:\/\/doi.org\/10.1093\/ageing\/afaf091.","journal-title":"Age Ageing"},{"issue":"13","key":"2672_CR3","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.jacc.2021.07.048","volume":"78","author":"ACT Ha","year":"2021","unstructured":"Ha ACT, Bhatt DL, Rutka JT, Johnston SC, Mazer CD, Verma S. Intracranial hemorrhage during dual antiplatelet therapy. J Am Coll Cardiol. 2021;78(13):1372\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2672_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1538-7836.2012.04641.x","volume":"10","author":"C Li","year":"2012","unstructured":"Li C, Hirsh J, Xie C, Johnston MA, Eikelboom JW. Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost. 2012;10(4):521\u20138.","journal-title":"J Thromb Haemost"},{"key":"2672_CR5","doi-asserted-by":"crossref","unstructured":"de Gea-Garc\u00eda JH, Fern\u00e1ndez-Vivas M, N\u00fa\u00f1ez-Ruiz R, Rubio-Alonso M, Villegas I, Mart\u00ednez-Fresneda M. Antiplatelet therapies are associated with hematoma enlargement and increased mortality in intracranial hemorrhage. Medicina Intensiva (English Edition) [Internet]. 2012 Nov [cited 2026 Feb 5];36(8):548\u201355. Available from: https:\/\/medintensiva.org\/en-antiplatelet-therapies-are-associated-with-articulo-S2173572712001361","DOI":"10.1016\/j.medine.2012.10.010"},{"key":"2672_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/298767","volume":"2014","author":"T Kapapa","year":"2014","unstructured":"Kapapa T, R\u00f6hrer S, Struve S, Petscher M, K\u00f6nig R, Wirtz CR, et al. Desmopressin acetate in intracranial haemorrhage. Neurol Res Int. 2014;2014:1\u20137.","journal-title":"Neurol Res Int"},{"issue":"5","key":"2672_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/ejh.13930","volume":"110","author":"A Mohinani","year":"2023","unstructured":"Mohinani A, Patel S, Tan V, Kartika T, Olson SR, DeLoughery TG, et al. Desmopressin as a hemostatic and blood sparing agent in bleeding disorders. Eur J Haematol. 2023;110(5):470\u20139.","journal-title":"Eur J Haematol"},{"issue":"8","key":"2672_CR8","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1161\/STROKEAHA.114.006061","volume":"45","author":"AM Naidech","year":"2014","unstructured":"Naidech AM, Maas MB, Levasseur-Franklin KE, Liotta EM, Guth JC, Berman M, et al. Desmopressin improves platelet activity in acute intracerebral hemorrhage. Stroke. 2014;45(8):2451\u20133.","journal-title":"Stroke"},{"key":"2672_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jocn.2021.01.017","volume":"86","author":"A Loggini","year":"2021","unstructured":"Loggini A, El Ammar F, Darzi AJ, Mansour A, Kramer CL, Goldenberg FD, et al. Effect of desmopressin on hematoma expansion in antiplatelet-associated intracerebral hemorrhage: a systematic review and meta-analysis. J Clin Neurosci. 2021;86:116\u201321.","journal-title":"J Clin Neurosci"},{"issue":"7","key":"2672_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.47102\/annals-acadmedsg.2025104","volume":"54","author":"SC Iyer","year":"2025","unstructured":"C Iyer S, Yap QV, Soong J, Cove M. Bayesian meta-analysis in the 21st century: fad or future of evidence synthesis? Ann Acad Med Singap. 2025;54(7):437.","journal-title":"Ann Acad Med Singap"},{"issue":"1","key":"2672_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/147078530905100107","volume":"51","author":"R Kent","year":"2009","unstructured":"Kent R. Rethinking data analysis - part one: the limitations of frequentist approaches. Int J Mark Res. 2009;51(1):1\u201314.","journal-title":"Int J Mark Res"},{"key":"2672_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2022-111928","author":"B Sadeghirad","year":"2022","unstructured":"Sadeghirad B, Foroutan F, Zoratti MJ, Busse JW, Brignardello-Petersen R, Guyatt G, et al. Theory and practice of Bayesian and frequentist frameworks for network meta-analysis. BMJ Evid Based Med. 2022. https:\/\/doi.org\/10.1136\/bmjebm-2022-111928.","journal-title":"BMJ Evid Based Med"},{"key":"2672_CR13","volume-title":"Cochrane handbook for systematic reviews of interventions","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editors. Cochrane handbook for systematic reviews of interventions. Wiley; 2019."},{"key":"2672_CR14","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. British Medical Journal [Internet]. 2021;372(71). Available from: https:\/\/www.bmj.com\/content\/372\/bmj.n71"},{"key":"2672_CR15","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ [Internet]. 2016;355(355):i4919. Available from: https:\/\/www.bmj.com\/content\/355\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"issue":"1","key":"2672_CR16","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366(1):l4898.","journal-title":"BMJ"},{"key":"2672_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","author":"LA McGuinness","year":"2020","unstructured":"McGuinness LA, Higgins JPT. Risk\u2010of\u2010bias VISualization (robvis): an R package and Shiny web app for visualizing risk\u2010of\u2010bias assessments. Res Synth Methods. 2020. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Methods"},{"key":"2672_CR18","doi-asserted-by":"crossref","unstructured":"R\u00f6ver C. Bayesian random-effects meta-analysis using the bayesmeta R package. Journal of Statistical Software. 2020;93(6).","DOI":"10.18637\/jss.v093.i06"},{"issue":"6","key":"2672_CR19","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/sim.6381","volume":"34","author":"RM Turner","year":"2014","unstructured":"Turner RM, Jackson D, Wei Y, Thompson SG, Higgins JPT. Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. Stat Med. 2014;34(6):984\u201398.","journal-title":"Stat Med"},{"key":"2672_CR20","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ [Internet]. 2008 Apr 24;336(7650):924\u20136. Available from: https:\/\/www.bmj.com\/content\/336\/7650\/924","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2672_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ajem.2025.03.052","volume":"93","author":"MA Rech","year":"2025","unstructured":"Rech MA, Brown C, Slocum GW, Gilbert BW, Aggarwal D, Howington GT, et al. Impact of desmopressin on hematoma expansion in patients presenting to the emergency department on antiplatelet therapy. Am J Emerg Med. 2025;93:126\u201331.","journal-title":"Am J Emerg Med"},{"key":"2672_CR22","doi-asserted-by":"publisher","first-page":"120142","DOI":"10.1016\/j.jns.2022.120142","volume":"434","author":"J McManus","year":"2022","unstructured":"McManus J, Ferreira J, Jones GM, Smetana KS, Smith Condeni M, Berger K, et al. Effect of desmopressin acetate on acute spontaneous intracranial hemorrhage in patients on antiplatelet therapy. J Neurol Sci. 2022;434:120142\u201352.","journal-title":"J Neurol Sci"},{"issue":"7","key":"2672_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S1474-4422(23)00157-6","volume":"22","author":"MJR Desborough","year":"2023","unstructured":"Desborough MJR, Al-Shahi Salman R, Stanworth SJ, Havard D, Woodhouse LJ, Craig J, et al. Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial. Lancet Neurol. 2023;22(7):557\u201367.","journal-title":"Lancet Neurol"},{"key":"2672_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jocn.2019.05.032","volume":"66","author":"KJ Schmidt","year":"2019","unstructured":"Schmidt KJ, Sager B, Zachariah J, Raad BF, James EG, Fletcher JJ. Cohort analysis of desmopressin effect on hematoma expansion in patients with spontaneous intracerebral hemorrhage and documented pre-ictus antiplatelet use. J Clin Neurosci. 2019;66:33\u20137.","journal-title":"J Clin Neurosci"},{"key":"2672_CR25","doi-asserted-by":"crossref","unstructured":"Feldman EA, Meola G, Zyck S, Miller CD, Krishnamurthy S, Cwikla GM, et al. Retrospective assessment of desmopressin effectiveness and safety in patients with antiplatelet-associated intracranial hemorrhage. Critical Care Medicine [Internet]. 2019 Dec 1;47(12):1759\u201365. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31567345\/","DOI":"10.1097\/CCM.0000000000004021"},{"key":"2672_CR26","unstructured":"Pang-Ting H, Chien SC, Chen CC, Liu ZH, Chuang CC, Tsai YC, et al. Impact of desmopressin on clinical outcomes in patients with spontaneous antiplatelet-associated intracerebral hemorrhage undergoing neurosurgical intervention: an observational multi-center study. Shock. 2025 Sep 5;"},{"key":"2672_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004348","author":"A Mengel","year":"2020","unstructured":"Mengel A, Stefanou MI, Hadaschik KA, Wolf M, Stadler V, Poli K, et al. Early administration of desmopressin and platelet transfusion for reducing hematoma expansion in patients with acute antiplatelet therapy associated intracerebral hemorrhage. Crit Care Med. 2020. https:\/\/doi.org\/10.1097\/CCM.0000000000004348.","journal-title":"Crit Care Med"},{"issue":"8","key":"2672_CR28","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1212\/01.wnl.0000208408.98482.99","volume":"66","author":"SM Davis","year":"2006","unstructured":"Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66(8):1175\u201381.","journal-title":"Neurology"},{"issue":"2","key":"2672_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s12028-019-00899-x","volume":"33","author":"JF Barletta","year":"2020","unstructured":"Barletta JF, Abdul-Rahman D, Hall ST, Mangram AJ, Dzandu JK, Frontera JA, et al. The role of desmopressin on hematoma expansion in patients with mild traumatic brain injury prescribed pre-injury antiplatelet medications. Neurocrit Care. 2020;33(2):405\u201313.","journal-title":"Neurocrit Care"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-026-02672-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-026-02672-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-026-02672-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:27:43Z","timestamp":1791829663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-026-02672-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":29,"alternative-id":["2672"],"URL":"https:\/\/doi.org\/10.1007\/s12028-026-02672-3","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no financial or other competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used Gemini Pro during the writing and grammar-checking process. After using this tool, the authors reviewed and edited the content as needed and took full responsibility for the content of the published article.","order":2,"name":"Ethics","label":"Artificial Intelligence","group":{"name":"EthicsHeading","label":"Declarations"}}]}}